Bio Essence Corp (BIOE)
BIOE is quoted over the counter, not listed on an exchange. Bio Essence Corp files reports with the SEC; the numbers below come from SEC filings and from daily closes, each with its source.
Closes: Yahoo Finance daily closes, last bar 2026-11-13.
Profile
| Field | Value |
|---|---|
| Ticker | BIOE, quoted over the counter |
| SEC CIK | 0001723059 |
| OTC Markets tier | OTCQB (price source, 2026-11-13) |
| SEC industry code | Pharmaceutical Preparations |
| Business address | Irvine, CA |
| Incorporated in | CA |
Warning signs
| Sign | Finding | Source |
|---|---|---|
| Going concern | States substantial doubt about continuing as a going concern. "These conditions raise substantial doubt about the Company's ability to continue as a going concern." | 10-Q 2026-11-13 |
| Cash and burn | $202K cash; operating cash flow $130K a quarter. | Report 2026-09-30 |
| Shares outstanding | 53,809,000 (2026-11-12); 38,009,000 a year earlier; 38,009,000 three years earlier. | Cover page 2026-11-12 |
| Reverse splits, 3 years | None found | None on EDGAR |
| Shelf and offerings, 12 months | 0 S-3/F-3 shelf filings; 0 424B5 takedowns | None on EDGAR |
| Exchange deficiency notices, 12 months | None | None on EDGAR |
| Auditor | Simon & Edward, LLP, Rowland Heights, California, United States | PCAOB Form AP 2026-04-07 |
| Late filings, 12 months | None | None on EDGAR |
| Insider trades, 12 months | Bought $0, sold $0 on the open market | SEC Forms 3/4/5 data sets 2026-09-30 |
From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.
Quarterly results
| Quarter | Revenue | Net income | Op. cash flow | Cash | Total debt | TTM revenue | Source |
|---|---|---|---|---|---|---|---|
| Q3 2026 2026-09-30 | $253K | -$150K | -$369K | $202K | $57K | $3.0M | 10-Q 2026-11-13 |
| Q2 2026 2026-06-30 | $795K | $270K | $60K | $675 | $57K | $2.9M | 10-Q 2026-08-14 |
| Q1 2026 2026-03-31 | $501K | $205K | -$412K | $36K | $57K | $2.4M | 10-Q 2026-05-15 |
| Q4 2025 2025-12-31 | $1.5M | $1.0M | $1.2M | Not filed | $57K | $1.9M | 10-K 2026-03-27 |
| Q3 2025 2025-09-30 | $137K | $13K | $187K | $29K | $58K | $566K | 10-Q 2026-11-13 |
| Q2 2025 2025-06-30 | $259K | $60K | $168K | Not filed | $58K | $564K | 10-Q 2026-08-14 |
| Q1 2025 2025-03-31 | $22K | -$206K | -$26K | Not filed | $56K | $346K | 10-Q 2026-05-15 |
| Q4 2024 2024-12-31 | $148K | -$28K | $423K | $1K | $56K | $324K | 10-K 2026-03-27 |
From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).
Key SEC documents
| Document | Form | Filed |
|---|---|---|
| Latest prospectus or offering document | 1-A | 2025-10-17 |
| Latest annual report | 10-K | 2026-03-27 |
| Latest quarterly / interim | 10-Q | 2026-11-13 |
| Latest current report | 8-K | 2026-10-23 |
Source: SEC EDGAR submissions feed, 88 recent filings. All filings on EDGAR.
The full dossier has every filing, quarterly and annual financials, the health record and a price chart.
Open the full dossier